98%
921
2 minutes
20
Background: Intracellular calcium contributes to the development of affective disorders. Also, calcium channel inhibitors influence the activity of many neurotransmitters and exert antidepressant and anxiolytic properties.
Objectives: The aim of this study was to examine the effects of sertraline on anxiety and depressive behaviors and the role of nimodipine, a calcium channel antagonist, on these effects.
Material And Methods: Forced swimming and elevated plus maze tests were used to assess depression and anxiety respectively in rats. Sertraline (10 mg/kg) was administered repeatedly for 7 days both alone and in combination with single (0.5 mg/kg) and repeated (0.5 mg/kg/7 days) nimodipine administrations.
Results: Both repeated sertraline (S) and its combination with single nimodipine administration (S + N) significantly decreased the immobility time compared to control. The combination of (S) with repeated doses of nimodipine (N/7d), significantly increased the immobility time compared to (S) and (S + N). Single dose of nimodipine (N) significantly increased the immobility time compared to (S) and (S + N), and decreased the number of divings compared to control. There was no significant difference between groups in terms of struggle and the time spent in closed arms of the elevated plus maze.
Conclusions: There was no interaction between a single dose of sertraline and nimodipine when administered in combination, while repeated nimodipine administration reversed the antidepressant-like effect of sertraline. We suggest that L-type calcium channels are involved in the antidepressant-like effect of sertraline. Neither single nor repeated nimodipine administration had a significant effect on both depressive behaviour and anxiety. We also propose that there is no interaction between the effects of sertraline and nimodipine on anxitey behavior.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.17219/acem/37043 | DOI Listing |
Expert Opin Pharmacother
June 2018
a Neurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, and Sense Organs , University of Bari Aldo Moro, Bari , Italy.
Introduction: Pharmacotherapy for the treatment of depressive disorders in Alzheimer's Disease (AD) represents a clinical challenge. pharmacological options are often attempted after a period of watchful waiting (8-12 weeks). monoaminergic antidepressant drugs have shown only modest or null clinical benefits, maybe because the etiology of depressive symptoms in ad patients is fundamentally different from that of nondemented subjects.
View Article and Find Full Text PDFAdv Clin Exp Med
September 2014
Department of Pharmacology, Eskisehir Osmangazi University, Medical Faculty, Turkey.
Background: Intracellular calcium contributes to the development of affective disorders. Also, calcium channel inhibitors influence the activity of many neurotransmitters and exert antidepressant and anxiolytic properties.
Objectives: The aim of this study was to examine the effects of sertraline on anxiety and depressive behaviors and the role of nimodipine, a calcium channel antagonist, on these effects.
Psychiatr Pol
June 2000
Zakładu Farmakologii Katedry Farmakologii AM w Lodzi.
The paper discusses therapeutical approaches to Alzheimer's disease on the basis of pathological mechanisms responsible for neurodegeneration. Amyloid plaques called also senile plaques situated extracellularly cause loss of neurons, especially cholinergic neurons, that begin in Nucleus of Meynert. However, recent evidence from postmortem brain and fibroblast studies suggests that both adenylyl cyclase and phosphatidylinositol hydrolysis signal transduction cascades are disrupted in AD.
View Article and Find Full Text PDF